The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $478.12, a high ...
Vertex halts VX-264 trials after missing efficacy goals but continues advancing zimislecel, a potential treatment for severe ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback